# A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

Source: https://onco.cc/trials/nct06590246/  
OnCo record `nct06590246` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Armored and GPC3-targeted autologous CAR T-cell in hepatocellular carcinoma, run by Shanghai AbelZeta Ltd., now recruiting.

## Summary

A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06590246 by Shanghai AbelZeta Ltd., with 121 participants planned, started 2024-09-30 and due to reach its primary completion in 2030-04-30. Interventions recorded: Armored and GPC3-targeted autologous CAR T-cell.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06590246
- Phase: 1/2
- Setting: Phase I/II Clinical Study of Armored and GPC3-targeted Autologous Chimeric Antigen Receptor (CAR) T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
- Sponsor: Shanghai AbelZeta Ltd.
- Enrolled: 121

## Sources

- ClinicalTrials.gov NCT06590246: https://clinicaltrials.gov/study/NCT06590246

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- companies: [Shanghai AbelZeta](https://onco.cc/companies/shanghai-abelzeta/)

---
JSON: https://onco.cc/api/v1/entities/nct06590246.json